MaxCyteMXCT -0.82%59 Net Debt Paydown Yield % is 0.31% as of Jul. 05, 2026. GuruFocus rates MXCT with a GF Score™ of 59/100 and a GF Value™ of $2.57 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 773 Medical Devices & Instruments companies, MaxCyte ranks better than 62.48% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, MaxCyte's Net Debt Paydown Yield % was 0.31%.
MaxCyte (NAS:MXCT) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
The historical data trend for MaxCyte's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MXCT vs RCEL, HYPR, CVRX: Net Debt Paydown Yield % Comparison
For the Medical Devices subindustry, MaxCyte's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Net Debt Paydown Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where MaxCyte's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of 0.31% mean?
MaxCyte (MXCT) has a Net Debt Paydown Yield % of 0.31% as of Jul. 05, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on MaxCyte and its competitors. According to the industry distribution chart, MaxCyte ranks #290 out of 773 companies in the Medical Devices & Instruments industry, placing it in the top 37.5%.
Is MaxCyte's Net Debt Paydown Yield % too high?
MaxCyte's current Net Debt Paydown Yield % is 0.31%. The Medical Devices & Instruments industry median Net Debt Paydown Yield % is 0.01. MaxCyte's value of 0.31% is 3000% above this industry median. Based on the distribution chart, MaxCyte ranks #290 out of 773 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, MaxCyte has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Net Debt Paydown Yield % compare to RCEL and HYPR?
According to the Medical Devices & Instruments industry distribution chart, MaxCyte ranks #290 out of 773 companies for Net Debt Paydown Yield %. This puts MaxCyte in the upper half of its industry. The industry median Net Debt Paydown Yield % is 0.01. MaxCyte's value of 0.31% is 3000% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Devices & Instruments company?
The median Net Debt Paydown Yield % among Medical Devices & Instruments companies is 0.01, based on 773 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MaxCyte's current Net Debt Paydown Yield % of 0.31% is 3000% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on MaxCyte and its competitors. For the Medical Devices & Instruments industry, the median Net Debt Paydown Yield % is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MaxCyte's current Net Debt Paydown Yield % is 0.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.22 — trading 52.7% below its estimated fair value. The current Net Debt Paydown Yield % is 0.31% and 3000% above the Medical Devices & Instruments industry median of 0.01. MaxCyte's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For MaxCyte (MXCT), the current Net Debt Paydown Yield % is 0.31% as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.22 is trading 52.7% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Net Debt Paydown Yield %: 0.31%
GF Value™: $2.57 vs. price of $1.22 (52.7% below fair value)
Industry Position: 3000% above the Medical Devices & Instruments median (#290 of 773)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
59GF Score
Get the complete analysis for MXCT
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
